Lv4
470 积分 2022-10-20 加入
RAF inhibitors that evade paradoxical MAPK pathway activation
4小时前
待确认
Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients
1个月前
已完结
Real‐World Efficacy and Safety of MEK Inhibitor for Patients With Advanced NRAS ‐Mutant Melanoma: A Single‐Center Retrospective Study in Japan
1个月前
已完结
Analysis of NRAS gain in 657 patients with melanoma and evaluation of its sensitivity to a MEK inhibitor
1个月前
已完结
Atezolizumab, cobimetinib, and vemurafenib as first-line treatment for unresectable metastatic BRAF V600 mutated melanoma
3个月前
已完结
Putative allosteric MEK1 and MEK2 inhibitors
10个月前
已完结
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
1年前
已完结
Risk of peripheral edema in cancer patients treated with MEK inhibitors: a systematic review and meta-analysis of clinical trials
1年前
已完结
The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics
1年前
已完结
皖公网安备34019202002308
